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An underlying endothelial dysfunction plays a fundamental role in the pathogenesis of cardiovascular events and is the central
feature of atherosclerosis. The protein-based communication between leukocytes and inflamed endothelial cells leading to
diapedesis has been largely investigated and several key players such as IL6, TNF𝛼, or the damage associated molecular pattern
molecule (DAMP) calprotectin are now well identified. However, regarding cytokine IL27, the controversial current knowledge
about its inflammatory role and the involved regulatory elements requires clarification. Therefore, we examined the inflammatory
impact of IL27 on primary endothelial cells and the potentially modulatory effect of calprotectin on both transcriptome and
proteome levels. A qPCR-based screening demonstrated high IL27-mediated gene expression of IL7, IL15, CXCL10, and CXCL11.
Calprotectin time-dependent downregulatory effects were observed on IL27-induced IL15 and CXCL10 gene expression. A mass
spectrometry-based approach of IL27 ± calprotectin cell stimulation enlightened a calprotectin modulatory role in the expression
of 28 proteins, mostly involved in the mechanism of leukocyte transmigration. Furthermore, we showed evidence for STAT1
involvement in this process. Our findings provide new evidence about the IL27-dependent proinflammatory signaling which
may be under the control of calprotectin and highlight the need for further investigations on molecules which might have
antiatherosclerotic functions.
1. Introduction
Atherosclerosis is characterized by the narrowing of arteries
caused by plaque formation and is a prominent representative
of cardiovascular diseases [1, 2]. Interestingly, development
of atherosclerosis occurs often prior to other cardiovascu-
lar events such as strokes or heart attacks. Under healthy
conditions, the vascular system contains an endothelium
composed of a monolayer of cells and forms a barrier
between the circulating blood and the vessel wall [3]. The
autocrine, paracrine, and endocrine mechanisms of the
vascular endothelium can exert modulatory effects like the
capacity to regulate cell activation as well as proliferation
influencing the growth and metabolism of the surrounding
tissue [4]. Furthermore, it has a key role being a gatekeeper
by regulating leukocyte trafficking between the blood and
the underlying tissue [5]. Alterations of endothelial functions
can be caused by several risk factors including smoking,
hypercholesterolemia, hyperglycemia, genetic factors, hyper-
tension, ageing, or inflammation [1, 2, 6–8]. While a normal
quiescent endothelium induces almost no expression of
proinflammatory molecules [6], the recognition of endo-
and exogenous danger signals by endothelial cells (ECs) can
lead to inflammatory responses through the expression of
adhesion molecules, secretion of inflammatory proteins, and
morphological changes of ECs [9, 10].
A key event in the early vascular inflammation process
is the recruitment and adhesion of leukocytes prior to
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transendothelial migration into inflammatory sites, a mech-
anism which involves cytokines, hormones, pathogen asso-
ciated molecular pattern molecules (PAMPs), and damage
associated molecular pattern molecules (DAMPs) [11, 12].
The role of cytokines and DAMPs, especially their athero-
genic activities and their involvement in the acceleration
of vascular diseases, is already well documented [13–18].
Regarding the IL6-family member IL27 cytokine, composed
of the subunits p28 and Epstein-Barr-virus-induced gene 3
(EBI3), its participation in immune responses and diseases
is more and more accepted [19]. Contradictory observations
regarding its pro- or anti-inflammatory role are however
reported [20, 21]. It has been shown in vivo that IL27
reduced inflammation by suppressing excessive Th1 immune
responses during infection, and in vitro in several T cell
subtypes it has been shown that IL27 induced the production
of the anti-inflammatory IL10 [22, 23]. More recently, the
anti-inflammatory role of IL27 as an upstream activator of
the STAT3 pathway was also established [24]. In the context
of atherosclerosis, Hirase and coworkers demonstrated that
mice with IL27 receptor deficiencies develop atherosclerotic
lesions [25].
On the other side, other data rather strive for proinflam-
matory activity of IL27, as described by Guzzo and collabo-
rators in primary monocytes [26] or by Nam and coworkers
who demonstrated that IL27 is secreted frompre- and normal
adipocytes under inflammatory conditions [27]. Moreover,
in terms of atherosclerosis development, IL27 is known to
induce in HUVECs the upregulation of the chemokines
CXCL9 and CXCL10, implicated in the transendothelial cell
migration [19, 28]. In a human study, higher serum levels of
IL27 were detected in patients suffering from coronary artery
diseases (CAD) such as myocardial infarction and stable
and unstable angina pectoris [29]. A pathway analysis of
primary tissue from different coronary atherosclerotic lesion
demonstrated an upregulation of IL27 in the early developed
lesions of atherosclerotic material, which emphasizes an
important role of IL27 in the development of atherosclerosis
[30]. Altogether these contradictory data about the exact role
of IL27 in inflammation suggest the existence of cytokine-
specific regulation processes occurring during cell to cell
communication.
Calprotectin, a S100A8/S100A9 heterodimer member
of the S100 protein family, is also known to be involved
in acute and chronic inflammation [31, 32]. Most of the
publications propose a proinflammatory function for calpro-
tectin, and regarding the development and progression of
atherosclerosis, both in vitro and in vivo studies suggest a
proatherogenic role for calprotectin [33–36]. On the contrary,
it has been reported that administration of calprotectin
induces immunosuppressive functions in rat animal models
[37, 38], indicating that, similar to IL27, calprotectinmay have
opposite regulatory functions.
In this study, we enlightened the involvement of IL27 and
calprotectin in the regulation of the inflammatory state of the
endothelium in terms of pro- and antiatherogenic functions.
Moreover, with the aim of identifying potential synergistic,
additive, or antagonistic effects from other mediators, we
analysed the role of calprotectin in IL27-mediated transcrip-
tome and proteome regulation.
2. Materials and Methods
2.1. HUVEC Isolation, Purification, and Activation. After
informed consent of parturients (Comite´ National D’Ethique
de Recherche Luxembourg 2013/01v1.0), primary Human
Umbilical Vein Endothelial cells (HUVECs) were isolated
with 1mg/mL collagenaseNB4 (SERVA) from fresh umbilical
cord veins from planned C-sections (protocol adapted from
[39]).TheHUVEC cell cultures were grown on 0.2% gelatine-
coated tissue flasks and with complete M199 (SIGMA)
supplemented with EGM2 SingleQuots (LONZA, Verviers,
Belgium) and 2mM L-glutamine (SIGMA) at 37∘C in humid
atmosphere with 5% CO
2
. Purity of HUVEC cell cultures
was assessed by flow cytometry; the following antibod-
ies were used: mouse anti-human CD31-PE, mouse anti-
human CD144-A647, and mouse anti-human CD146-PerCP-
Cy5.5 antibodies (all from BD Sciences, Erembodegem,
Belgium). Passage numbers 2–4 were used for the activation
of HUVECs. Stimulation experiments with HUVECs were
prepared with a cell density of 2.5 × 105 cells/mL in 6-well
plates (Greiner, Vilvoorde, Belgium) with 1mL/well complete
M199 media for 24 h, and with a subsequent depletion phase
of 12 hwith EGM2SingleQuots-depletedM199media supple-
mented with 2% FBS (LONZA), gentamycin (LONZA), and
2mM L-glutamine (SIGMA, MA). To determine the optimal
stimulation concentrations, HUVECswere incubated for 12 h
with ranges of 10, 30, and 100 ng/mL IL27 (R&D Systems,
Abingdon, UK) and 1, 5, and 10 𝜇g/mL calprotectin (Hycult,
Uden, Netherlands) (3 biological replicates). In the costim-
ulation assays, for transcriptome analysis, HUVECs were
stimulated with IL27 (30 ng/mL) ± calprotectin (1𝜇g/mL) for
3, 6, 12, and 24 h (6 biological replicates) and for intracellular
proteome analysis a time course of 6, 12, and 24 h was
performed (9 biological replicates). Furthermore, HUVECs
were stimulated with TNF𝛼 (2 ng/mL) (Peprotech, NJ) ±
calprotectin (1𝜇g/mL) for 3, 6, 12, and 24 h (3 biological
replicates). Stimulations were stopped by washing the adher-
ent HUVECs with 1mL of ice cold sterile PBS and the
6-well plates were directly frozen at −80∘C. Cell viability
was assessed by LDH release using cytox96 nonradioactivity
cytotoxicity assay (Promega, Leiden, Netherlands).
2.2. RNA Extraction and RT-qPCR. RNA extraction from
HUVECs was performed according to the instructions and
solutions of the ReliaPrep RNA Cell Miniprep System
(Promega). 250𝜇L of the lysis buffer was added to each well
and cells were scratched off. Afterwards, purified RNA was
eluted with 30 𝜇L nuclease-free water. RNA yield and purity
were determined by spectrophotometer NANOdrop 2000
(Thermo Scientific, CA). For reverse transcription, 0.2 𝜇g
random primer (Promega) was added to 1𝜇g RNA and
incubated for 5min at 70∘C, followed by a subsequent addi-
tion of 5x reaction buffer, 20U (final) RNAsin Ribonuclease
inhibitor (Promega), 0.5mM (final) dNTP (Promega), and
160U (final) GoScript reverse transcriptase (Promega) with
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incubations of 5min at 25∘C, 60min at 42∘C, and 10min at
70∘C.
For determination of optimal stimulation concentration,
a 96-multigene array TaqMan Human Immune panel (cat.
4370573) was used. The cDNA (437.5 ng) was mixed with
TaqMan Universal Master mix II (Applied Biosystems, CA)
and added per well. Parameters for qPCR were set as follows:
2min at 50∘C, 10min at 95∘C, and 40 repetitions of 15 s at 95∘C
and 60 s at 60∘C (QuantStudio 12K Flex v1.1, Applied Biosys-
tems). Data analysis was performed by Expression Suite v1.1
software. For time course analysis, the following TaqMan
primers were used: IL7Hs00174202 m1, IL15Hs00174106 m1,
CXCL10 Hs00171042 m1, CXCL11 Hs00171138 m1, and the
HKGs ACTB Hs99999903 m1, GAPDH Hs99999905, and
GUSB Hs99999908 m1. In total, 25 ng of cDNA was mixed
with TaqMan Universal Master mix II (Applied Biosystems)
and added per well of aMicroAmpFast 96-well plate (Applied
Biosystems). Parameters for qPCR were set as follows: 10min
at 93∘C and 40 repetitions of 15 s at 95∘C and 60 s at 60∘C
(QuantStudio 12K Flex v1.1, Applied Biosystems).
Quantitative analysis was performed by the method of
Willems and collaborators [40]. Internal normalization was
performed to ACTB, GAPDH, and GUSB housekeeping
genes (HKGs).
2.3. Proteomics
2.3.1. Sample Preparation. For cells lysis, 50 𝜇L 8M urea
was added directly to each well and cells were scratched
off, transferred, and subsequently sonicated for 1 h at 4∘C.
Afterwards 200𝜇L of 0.8% RapiGest (Waters) within 50mM
NH
4
HCO
3
and 2mM DTT were added and incubated for
1 h at room temperature (RT), followed by addition of 10mM
MMTS (Pierce, Erembodegem, Belgium) and incubation of
1 h at RT in the dark. Digestion of proteins in peptides
was achieved by addition of 1 𝜇g Trypsin Gold (Promega)
for 24 h at RT and stopped by addition of 1% TFA for 1 h
at RT. Afterwards samples were salted out by using 3M
Empore cartridges (3M Bioanalytical, MS). Samples were
loaded on cartridges, eluted with 200𝜇L of 70% acetonitrile
(ACN) within 0.1% TFA, and further dried in vacuum
centrifuge (Speedvac,Thermo Scientific). Dried sampleswere
resuspended with 20 𝜇L of 0.1% TFA. Samples were loaded
on Zip Tips C18 (ZTC18S960, Millipore, Molsheim, France)
and eluted with 20 𝜇L 70% ACN within 0.1% TFA and dried
in vacuum centrifuge (Speedvac, Thermo Scientific). Before
measurement, samples were resuspended in 10 𝜇L of 2%ACN
within 0.1% TFA.
2.3.2. LC-MS/MS. Peptide analysis was performed by LC-
MS/MS on an EASY-nLC Ultra HPLC (Thermo Scientific)
coupled to a hybrid dual-pressure linear ion trap/orbitrap
mass spectrometer (LTQ Orbitrap Velos Pro, Thermo Scien-
tific). Dissolved peptide samples were separated on a 75𝜇m
(inner diameter), 25 cm, PepMap C18-column (Dionex-
Thermo Sciences). A solution gradient ranging from 2%
to 40% ACN within 0.1% formic acid at a constant flow
rate of 300 nL/min for 200min enabled the preseparation
of peptides. Eluting peptides were ionized in a nanospray
interface. Regarding the MS/MS settings, collision-induced
dissociation (CID) was applied for the 15 most abundant
ions detected in the full MS scan. Essential MS settings
were as follows: full MS (FTMS; resolution 60000; 𝑚/𝑧
range 400–2000) and MS/MS (linear trap; minimum signal
threshold 500; isolation width 2Da; dynamic exclusion time
setting 30 s; singly charged ionswere excluded from selection;
normalized collision energy was set to 35% and activation
time to 10ms).
2.3.3. Label-Free Quantification. Progenesis QI for pro-
teomics (Waters, Nonlinear Dynamics, MA) was used for
label-free quantification of LC-MS derived data. First, align-
ment of the two-dimensional ion intensity map representing
the retention time and mass to charge ratio of peptides was
performed, followed by quantification of signals and finally
peptide and protein identification by database search. In
order to rely on proteins that were confidently identified,
a cut-off for at least two unique peptides per protein was
applied.
2.3.4. Data Normalization. Theprogenesis QI for proteomics
quantified proteins was still skewed toward high abundances.
Thus, abundances were further processed by using 𝑅 (v3.2.1,
[41]) for data normalization using the 𝑅 bioconductor pack-
age variance stabilization and normalization (VSN [v3.36.0],
[42]) and the function vsn2.
In order to assess the variability between the biological
replicates, calculation of the peak sum per replicate was
performed; that is, a ratio between each protein abundance to
the sum of all protein abundances of the considered replicate
was calculated. Afterwards for each time point, the peak sum
medians per replicates and a peak summedian of all replicates
were calculated. Application of a cut-off standard deviation
(sd) of 1.25 allowed an elimination of outlier replicates. In
detail, 2 replicates for the 6 h time point, 6 replicates for
the 12 h time point, and 7 replicates for the 24 h time point
were removed. Additionally, two biological replicates, control
replicates 1 and 2 for 𝑡 = 24 h, despite fulfilling the cut-off of
sd of 1.25 showed a shifted distribution andwere subsequently
removed (Figures S1–S3 in Supplementary Material available
online at http://dx.doi.org/10.1155/2015/737310).
2.3.5. Differential Protein Expression Calculation. Retained
replicates were implemented to the Linear Models for
Microarray Data (limma) bioconductor 𝑅 package [v3.24.10],
for determination of differential expression [43].This package
was already successfully applied to proteomics [42, 44, 45].
limma uses an empirical Bayes 𝑡-test that takes into account
the global variance to avoid the noise of local variance for
small samples.
Correction for multiple testing was performed by com-
puting the false discovery rate (termed as 𝑞-values) using the
𝑝 values provided by limma and calculated using the 𝑅 bio-
conductor package 𝑞-value [v2.0.0] [46]. Lastly, logarithmic
base 2 FC (LogFC) values were converted back to original
log2FC using the function sinh. Plots were performed using
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the ggplot2 𝑅 package [v1.0.1] [47]. Significance threshold
of the 𝑞-values is determined by plotting 𝑞-values over 𝑝
values and identification of intersection (Figure S4) [45].
Statistically significant 𝑞-values were indicated with ∗𝑞 <
0.15, ∗∗𝑞 < 0.10, and ∗∗∗𝑞 < 0.01. Of note, all statistical
analyses were performed on amacOSX architecture (x86 64-
apple-darwin14.3.0 (64-bit)).
2.4. Western Blot. HUVEC samples were scratched off with
a Triton-x lysis buffer. A 10% tris-glycine polyacrylamide gel
was prepared and approximately 20 𝜇g protein was loaded
(mixed with 5x Laemmli buffer). 3𝜇L of PageRuler Plus
Prestained protein Ladder (Thermo Scientific) was trans-
ferred at least to one well, and samples of interest were
transferred to free wells of the gel. Furthermore, a 0.2 𝜇m
PVDF membrane was used. Antibodies were from BD
Biosciences: pSTAT1 pY701 (612233), STAT1 (610116), and
STAT3 (610190); cell signaling: pSTAT3 pY705 (9145S); Pierce
Thermo: tubulin (PA1-38814). Secondary antibodies were
anti-goat IRdye800CW (ODYSSEY, 926-32214) and anti-
mouse Alexa Fluor 680 (Invitrogen, A10038). Membranes
were detected by fluorescent labelled target proteins, a photo
sensor of the LI-COR Odyssey Infra-Red Imaging System
(LI-COR, NE). For densitometry analysis, pSTAT1 (𝑛 = 3)
and pSTAT3 (𝑛 = 3) were normalized to tubulin.
2.5. Pathway Analysis. Data were analysed through the use of
QIAGEN’s Ingenuity Pathway Analysis (IPA, QIAGEN Red-
wood City; http://www.ingenuity.com/). Normalized tran-
scriptome data of different concentrations per stimulus and
proteomic data of 6, 12, and 24 h were merged, respectively.
Core analyses were performed with the following settings: 𝑝
value < 0.05 (transcriptome data) or 𝑞-value < 0.15 (proteome
data); reference set was the Ingenuity Knowledge Base (Genes
+ Endogenous Chemicals), where only experimental obser-
vations, direct and indirect relationships, and the Fisher exact
𝑡-test were chosen; the knowledge bases from all species and
all cell types were included. Regarding transcriptome data,
a comparative analysis of IL27- and calprotectin-regulated
genes was performed and the top 20 biological functionswere
chosen based on scoring the 𝑧-scores. Afterwards, a hier-
archical clustering was performed on the top 20 biological
functions based on Euclidean distance using the function
heatmap.2 from the 𝑅 package gplots.
2.6. Statistical Analysis. The statistical analysis was per-
formed using the software GraphPad Prism 5 (GraphPad
Software, La Jolla, CA, USA). For more than 5 biological
replicates and unequal variances, an unpaired 𝑡-test with
Welch’s correction and, for less than 5 biological replicates, an
unpaired 𝑡-test were applied. Statistically significant 𝑝 values
were indicated with ∗𝑝 < 0.05, ∗∗𝑝 < 0.01, and ∗∗∗𝑝 < 0.001.
3. Results
3.1. IL27 and Calprotectin-Dependent Regulation of the
Endothelial Cell Gene Expression. To examine the effect of
IL27 and calprotectin on endothelial cell gene expression, a
multiplex gene array analysis of 96 genes including cytokines,
growth factors, and other immune response genes was per-
formed. In order to optimize the stimulation concentrations
for IL27 and calprotectin, 3 different concentrations for
IL27 (10, 30, and 100 ng/mL) and for calprotectin (1, 5, and
10 𝜇g/mL) were used, according to published data [19, 33,
48]. The relationship of significant differentially expressed
genes following stimulationwith IL27 is shown in Figure 1(a).
Nineteen unique significantly expressed genes were found
amongwhich 15 were upregulated and 4were downregulated.
Interestingly, the highest upregulations were observed for
IL7, IL15, CXCL10, and CXCL11 (Table S1). Regarding cal-
protectin cell stimulation, 15 unique significantly expressed
genes were found, among which 11 genes were upregulated
and 4 genes were downregulated, with the gene PTGS2 being
upregulated after 1 and 10 𝜇g/mL calprotectin treatment and
downregulated after 5 𝜇g/mL calprotectin stimulation. The
highest differential gene expression was observed for IL7 and
CCL5 (Table S1).
We next performed functional gene enrichment analy-
ses using the Ingenuity Pathway Analysis (IPA) tool. The
significantly regulated unique genes were merged for each
stimulus. A core analysis was carried out and biological anno-
tation enrichment was generated based on genes. The top
20 biological functions derived from calprotectin and IL27-
regulated genes are shown in Figure 2. IL27-mediated gene
expression showed that IL27 activated all of the presented top
20 biological functions, including, for example, inflammatory
response and activation, stimulation, andmigration of leuko-
cytes (𝑧-score ≥ 2). However, calprotectin only mediated the
activation of 1 out of the 20 presented biological functions.
This pathway analysis reveals that while IL27 appears to be
involved in typical inflammatory functions, the activity of
calprotectin is less obvious.
3.2. Calprotectin-Dependent Modulatory Effects on IL27-
Mediated Gene Expression of IL7, IL15, CXCL10, and CXCL11.
To evaluate the possible role of calprotectin in the regulation
of the expression of the IL27-dependent upregulated genes
IL7, IL15, CXCL10, and CXCL11, HUVECs were treated with
IL27 (30 ng/mL) ± calprotectin (1𝜇g/mL) and the relative
gene expression was determined by RT-qPCR for the dif-
ferent time points 3, 6, 12, and 24 h as shown in Figure 3.
Calprotectin induced downregulation of IL27-mediated gene
expression of IL15 and CXCL10 while no significant effect
was observed neither on IL7 nor on CXCL11. Interestingly,
calprotectin decreased IL27-induced gene expression of IL15
by half at all time points, whereas its downregulating effect on
CXCL10 was weaker and limited to the early time points 3 h
and 6 h. These results point to a specific downregulatory role
of calprotectin in the endothelial IL27-dependent signaling
leading to gene expression of IL15 and CXCL10.
In order to confirm the proinflammatory activity for IL27
and the calprotectin modulatory effects, the HUVECs were
stimulated with TNF𝛼 (2 ng/mL) ± calprotectin (1𝜇g/mL)
for 3, 6, 12, and 24 h, and the gene expression of IL7, IL15,
CXCL10, and CXCL11 was analysed by RT-qPCR (Figure 4).
We observed similar TNF𝛼-mediated gene upregulation of
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Figure 1: Venn diagrams on IL27- and calprotectin-stimulated HUVECs including significant regulated genes with 𝑝 value 𝑝 < 0.05: red:
upregulated, green: downregulated, and black: up- and downregulation different in compared concentrations. (a) Venn diagram: HUVECs
stimulatedwith IL27 (10, 30, and 100 ng/mL). (b)Venndiagram:HUVECs stimulatedwith calprotectin (1, 5, and 10 𝜇g/mL).ACE, angiotensin-
converting enzyme; BCL2, B-cell lymphoma 2; BCL2L1, BCL2-like 1; C3, complement component 3; CD, cluster of differentiation; CSF, colony
stimulating factor; CCL2/MCP-1, monocyte chemotactic protein-1; CCL5/RANTES, regulated on activation, normal T cell expressed and
secreted; CXCL10, interferon gamma-induced protein 10; CXCL11, interferon-inducible T cell alpha chemoattractant; CYP7A1, cholesterol 7
alpha-hydroxylase; FAS, Fas cell surface death receptor; ICAM1, intercellular adhesionmolecule 1; IKBKB, inhibitor of kappa light polypeptide
gene enhancer in B-cells, kinase beta; IL, interleukin; LTA, lymphotoxin-𝛼; NFKB2, nuclear factor-kappa-B p100 subunit; NOS2A, inducible
nitric oxide synthase; PGK1, phosphoglycerate kinase 1; PTGS2, prostaglandin G/H synthase and cyclooxygenase; SELE, selectin E; SELP,
selectin P; SMAD3, mothers against decapentaplegic homolog 3; STAT, signal transducers and activators of transcription.
IL7, IL15, CXCL10, and CXCL11. Furthermore, calprotectin
induced downregulatory effects on TNF𝛼-mediated gene
expression of IL7, IL15, and CXCL10, hence validating our
previous findings and emphasizing the IL15- and CXCL10-
specific regulatory role of calprotectin.
3.3. Calprotectin-Dependent Modulatory Effects on IL27-
Mediated Intracellular Protein Expression. To investigate the
IL27-induced protein expression in HUVECs and to examine
the potential regulatory role of calprotectin in this pro-
cess, we used a label-free MS-based proteomic approach.
HUVECs were stimulated with IL27 (30 ng/mL) ± calpro-
tectin (1 𝜇g/mL) for 6, 12, and 24 h. In total, the number
of unique proteins detected for each time point was 1061
at 6 h, 994 at 12 h, and 886 at 24 h (Table 1). As shown
in Figure S4 by a representation of 𝑞-values over 𝑝 values
derived from proteome data, a significance cut-off threshold
corresponding to 𝑞-value <0.15 could be chosen. The data
indicated the following unique differentially regulated pro-
teins detected for each time step: 11 at 6 h, 143 at 12 h, and
193 at 24 h (Table 1). Furthermore, a time-dependent increase
for significant expressed proteins for IL27- and calprotectin-
stimulated HUVECs was observed. Interestingly, the costim-
ulation revealed already highest protein expression number
at 12 h suggesting a calprotectin modulatory role in IL27-
mediated protein expression (Table 1). As shown in Figure 5,
calprotectin time-dependent modulatory effects on protein
expression were observed on 28 unique proteins. Figure 6
summarizes qualitatively the modulatory role of calprotectin
in IL27-mediated protein expression. While calprotectin
potentialized the IL27-dependent expression of NMT1 (12 h)
and STAT1 (24 h) and upregulated STAT3 (6 h), it decreased
the expression of GBP1 andWARS at 24 h and downregulated
STAT1 at 6 h. Furthermore, calprotectin prevented the IL27-
mediated downregulation of NID1 and TPM1, as well as
the upregulation of 14 proteins: ARFGAP1, BASP1, CANX,
COPE, GNB2, GP1, GSTP1, HMOX2, PKM, PEBP1, PDLIM5,
RPL30, PSMA7, and YBX3. The results also showed that
the costimulation of HUVECs with IL27 + calprotectin
induced the downregulation of 5 proteins (FERMT3, H2B1C,
KP2, PECAM1, and SRSF7) whereas 2 proteins (AHSG and
S100A9) were upregulated. However, none of the proteins
corresponding to the genes induced by IL27 and regulated
by calprotectin were differentially expressed. These findings
emphasize at the protein level the role played by calprotectin
in the regulation of IL27-dependent protein expression.
3.4. Calprotectin-Dependent Modulatory Effects on IL27-
Mediated STAT1/3 Signaling. The signal transducers and
activators of transcription (STAT) 1 and 3 are both known
to be part of the signaling downstream cascade of IL27
and are activated through phosphorylation [49, 50]. Our
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Figure 2: Top 20 biological functions from a comparative gene enrichment analysis of IL27 and calprotectin-mediated gene expression. The
biological function gene enrichment analysis was carried out by IPA and represents the 𝑧-score (activation ≥ 2).
Table 1: Number of unique identified proteins without and with
q-value cut-off of 𝑞 < 0.15 of IL27 (30 ng/mL) ± calprotectin
(1 𝜇g/mL)-stimulated HUVECs for 6, 12, and 24 h.
Time point
6 h 12 h 24 h
Unique proteins
All identified 1061 994 886
q-value < 0.15 11 143 193
Condition (q-value < 0.15)
IL27 0 55 132
IL27 + calprotectin 10 96 20
Calprotectin 1 17 66
proteomic results clearly indicate that calprotectin upregu-
lated IL27-mediated STAT3 protein expression at 6 h whereas
protein expression of STAT1 was downregulated at 6 h and
upregulated at 24 h (Figure 5). We next analysed by western
blotting the phosphorylation levels of STAT1 and STAT3
when HUVECs were stimulated with IL27 (30 ng/mL) ±
calprotectin (1𝜇g/mL) for 3, 6, 12, and 24 h (Figures 7 and
S5). Interestingly, the IL27 + calprotectin cotreatment clearly
potentialized the IL27-mediated STAT1 phosphorylation at 12
and 24 h but had no effect on the STAT3 phosphorylation
over the time, suggesting that calprotectin might act through
the regulation of the STAT1 activity to modulate the IL27-
dependent proinflammatory signaling.
4. Discussion
The function of the cytokine IL27 in the inflammatory
mechanism leading to immune cell transmigration through
the endothelium is controversially discussed. In this study, we
investigated the potential IL27-dependent induced inflam-
matory responses regarding endothelial cell gene and pro-
tein expression in the context of vascular inflammation. In
addition, we propose that calprotectin may be involved in the
regulation of this process.
4.1. The Modulatory Role of Calprotectin in IL27-Mediated
Inflammation. Animal and human studies revealed contra-
dictory observations for the investigation of the atherogenic
role of the IL27. Studies in animal models have shown an
atheroprotective role whereas human studies demonstrated
an important proatherogenic role of IL27 in cardiovascular
disease [30, 51]. Our findings demonstrate that exposure of
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Figure 3: Effects of IL27, calprotectin, and IL27/calprotectin cotreatment on gene expression. Relative mRNA levels of IL7, IL15, CXCL10,
and CXCL11 of IL27 (30 ng/mL) ± calprotectin (1𝜇g/mL)-stimulated HUVECs for 3, 6, 12, and 24 h are represented as mean ± SEM (𝑛 = 6).
Indicated𝑝 values are corresponding to significant differences between IL27 and IL27 + calprotectin: ∗𝑝 < 0.05, ∗∗𝑝 < 0.01, and ∗∗∗𝑝 < 0.001.
HUVECs to different literature-based chosen IL27 concen-
trations results in differential gene expression of 19 out of
96 tested genes (Figure 1(a) and Table S1). Among these 19
genes, we observed 15 upregulated genes which are known to
be involved in inflammation. Our pathway analysis revealed
that the IL27-induced genes are highly involved in the acti-
vation of a variety of biological functions such as activation,
stimulation, and migration of leukocytes (Figure 2). Since
these functions are fundamental characteristics of the early
steps of atherosclerosis development, we propose not only
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Figure 4: Effects of TNF𝛼, calprotectin, and TNF𝛼/calprotectin cotreatment on gene expression. Relative mRNA levels of IL7, IL15, CXCL10,
and CXCL11 of TNF𝛼 (2 ng/mL) ± calprotectin (1𝜇g/mL)-stimulated HUVECs for 3, 6, 12, and 24 h are represented as mean ± SEM (𝑛 = 3).
Indicated 𝑝 values are corresponding to significant differences between TNF𝛼 and TNF𝛼 + calprotectin: ∗𝑝 < 0.05, ∗∗𝑝 < 0.01, and ∗∗∗𝑝 <
0.001.
a proinflammatory but also a proatherogenic role for IL27,
which is in agreement with the pathway analysis of King and
coworkers [30].
In human studies, the two calprotectin subunits S100A8
and S100A9 were detected in atherosclerotic plaques and
elevated in serum of patients suffering from peripheral artery
disease [52, 53]. In our study, stimulating HUVECs with dif-
ferent calprotectin concentrations revealed differential gene
expression of 16 out of 96 tested genes (Figure 1(b) and Table
S1).However, calprotectin-induced gene expression indicated
poor regulatory effects in terms of expression level (only 2
genes with FC > 1.5). Our observations are in accordance
with a study of Viemann and collaborators in which human
microvascular ECs were stimulated with 200𝜇g/mL calpro-
tectin for 6 h: although the calprotectin concentration used
was elevated, only 16 genes with a FC > 1.7 were induced and
proposed to be involved in promoting platelet aggregation,
inflammation, and endothelial permeability [54].
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Figure 5: Label-free quantified proteins represented as relative protein levels. The calprotectin significant modulatory effects on mutual
proteins in HUVECs stimulated with IL27 (30 ng/mL) ± calprotectin (1𝜇g/mL) are shown for 6, 12, and 24 h (𝑛 = 9). Significance is indicated
by 𝑞-value: ∗𝑞 < 0.15, ∗∗𝑞 < 0.10, and ∗∗∗𝑞 < 0.01. Significance is indicated for each stimulation by stars and between IL27 and IL27
+ calprotectin stimulation by stars with a line. AHSG, alpha-2-HS-glycoprotein; ARFGAP1, ADP-ribosylation factor GTPase-activating
protein 1; BASP1, brain acid soluble protein 1; CANX, calnexin; COPE, coatomer subunit epsilon; FERMT3, fermitin family homolog 3;
GBP1, interferon-induced guanylate binding protein 1; GNB2, guanine nucleotide-binding protein, subunit beta-2; GPI, glucose-6-phosphate
isomerase; GSTP1, glutathione S-transferase P; H2B1C, histoneH2B type 1; HMOX2, heme oxygenase 2; KP2, importin subunit alpha-1; NID1,
nidogen-1; NMT1, glycylpeptideN-tetradecanoyl transferase 1; PDLIM5, PDZ and LIMdomain protein 5; PEBP1, phosphatidylethanolamine-
binding protein 1; PECAM1, platelet/endothelial cell adhesion molecule; PSMA7, proteasome subunit alpha type-7; RPL30, 60S ribosomal
protein L30; S100A9, S100 calcium binding protein A9; SRSF7, serine/arginine-rich splicing factor 7; STAT, signal transducers and activators
of transcription; TPM1, tropomyosin 1; WARS, tryptophan tRNA ligase, cytoplasmic; YBX3, Y-box-binding protein 3.
In order to enlighten the role of calprotectin in our
experimental setup, our pathway analysis indicated that
the calprotectin-regulated genes were not implicated in the
typical activation and migration of leukocytes but solely
involved in the delayed hypersensitive reaction (Figure 2).
Based on this pathway analysis, we hypothesized a possible
calprotectinmodulatory activity in inflammatory response of
HUVECs. In order to clarify the inflammatory role of cal-
protectin, we investigated their potential synergistic, additive,
or antagonistic effects on transcriptome and proteome levels.
We first analysed the impact of calprotectin on HUVEC
gene expression level by focussing on the 4 most upregulated
genes upon IL27 stimulation (IL7, IL15,CXCL10, andCXCL11)
(Figure 3).
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Figure 7: Effects of IL27, calprotectin, and IL27 + calprotectin cotreatment on STAT1/3 phosphorylation. Relative protein levels of Tyr701-
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We observed clear calprotectin modulatory effects on
IL27-mediated IL15 and CXCL10 gene expression (Figures
3(b) and 3(c)). Interestingly, the stimulationwith calprotectin
reduced the IL27-mediated gene expressions of IL15 over the
entire studied time range and of CXCL10 at the early time
points (Figures 3(b) and 3(c)). Based on our observations,
we propose an anti-inflammatory role of calprotectin in
the IL27-mediated IL15 and CXCL10 gene expression. But
the cytokine IL27 is known to have pleiotropic functions
with pro- and anti-inflammatory capacities [20], which could
lead to misinterpretation of the anti-inflammatory function
proposed for calprotectin.Thus, we also stimulated HUVECs
with the potent proinflammatory TNF𝛼 in the presence
of calprotectin in the same conditions. Interestingly, simi-
lar calprotectin reducing effects were observed on TNF𝛼-
mediated gene expression (Figure 4), which highly supports
our hypothesis about the anti-inflammatory capacity of
calprotectin on IL27-stimulated HUVECs. Analysing only
the genome is not sufficient to completely understand a
phenotype or a disease development process. Therefore we
further analysed the intracellular proteome of whole cell
lysates of IL27 ± calprotectin-stimulated HUVECs by a shot-
gun label-free LC-MS/MS approach to gain greater insight
into our proposed anti-inflammatory capacity of calprotectin
in the context of endothelial inflammation. The label-free
quantification revealed a number of identified and quantified
proteins similar to the one of Gautier et al. [55], who
identified 725 unique proteins in untreated HUVEC samples.
Another shot-gun proteomic approach combined with label-
free quantification was also successfully applied to HUVECs
treated with a clinical phase III candidate [56]. In order to
further proceed with our data, we used the positive false
discovery rate also known as 𝑞-value, which controls the
false discoveries and corrects for multiple testing to calculate
the significance [57]. Indeed 𝑞-values were shown to provide
a more direct way of interpreting significance than the 𝑝
value in the context of quantitative proteomics [45]. In
our study, the direct comparison between 𝑝 values and 𝑞-
values using the well accepted significance threshold for 𝑝
value <0.05 revealed a 𝑞-value threshold of maximum 0.175
(Figure S4). Based on this result, we chose a significance
threshold of 𝑞-value <0.15, meaning that less than 15% of
our significant regulated proteins are false discoveries. This
finally revealed the numbers shown in Table 1 for significant
regulated proteins.
Our proteomic approach revealed that calprotectin mod-
ulated 28 unique proteins (Figure 5). Unfortunately, the
sample complexity of our whole HUVEC cell lysates did
not allow the determination of low abundant proteins such
as cytokines. Thus, the calprotectin inhibitory effect on
IL27-mediated gene expression of IL15 and CXCL10 could
not be examined on protein level by shot-gun LC-MS/MS.
However, higher protein levels of CXCL10 as well as CXCL11
were detected in human and carotid atherosclerotic tissues
whereas none of them were detected in normal vessel walls,
highlighting that both proteins are playing an important role
in the development of atherosclerosis [58].
Regarding our results, we therefore propose a model of a
calprotectin reducing effect on IL27-mediated inflammation
of the vascular endothelium in the context of atherosclerosis.
Figure 8 describes the possible mechanism of IL27-induced
vascular inflammation and the potential atheroprotective role
of calprotectin in this context. IL27 induced the secretion of
the chemokines CXCL10 and CXCL11 which are known to
attract monocytes as well as T cells. In more detail, CXCL10
and CXCL11 mainly recruit CD4 or CD8 T cells, which also
represent the main T cell subsets found in atherosclerotic
plaques [58–60]. CXCL10 and CXCL11 can bind via their
cognate receptor CXCR3which is highly expressed onmono-
cytes, T cells, andNK cells [61]. In the atherosclerotic context,
endothelial cells do not express CXCR3 but use a very defined
system [62]. CXC chemokines such as CXCL10 and CXCL11
can also bind, for example, to heparan sulfate proteoglycans,
which are present at the cell surface of endothelial cells. This
binding of CXCL10 and CXCL11 can facilitate the rolling of
monocytes and T cells on the vascular endothelium [62, 63].
Furthermore, it can facilitate the adhesion to other proteins
such as the transpresented IL15 at the surface of endothelial
cells. T cells and monocytes express the counterparts IL2R𝛼
and IL2R for IL15R to form the tridimeric IL15 receptor
[64]. Independent studies have shown the transendothelial
migration of T cells and monocytes through IL15 expression
on endothelial cells [64, 65].
Our proteome analysis revealed an IL27-induced regula-
tion of a variety of proteins which are involved in the inflam-
matory state of the endothelium as well as the development of
atherosclerosis. For example, the extracellular matrix glyco-
protein nidogen-1 (NID1) was highly downregulated by IL27.
NID1 belongs to the basementmembrane and is an important
linker between the extracellular matrix components collagen
and laminin [66]. It could be shown that suppression of
NID1 can influence the cell morphology from a flat to a
round shape by losing contact to the underlying basement
membrane. Thus, an important functional implication of
NID1 was suggested in the blood-vessel tissue barrier [67].
Furthermore, NID1 may be involved in the defense against
infiltration of cancer cells [68]. Another highly downregu-
lated protein by IL27 was tropomyosin 1 (TPM1), which is
known as a tumour suppressor. Suppression of TPM1 can
lead to the destabilization of the cytoskeleton [69]. It was
described that the initiation and growth of atheroma can
occur due to the loss of integrity of an intact endothelial
monolayer [70]. In the context of atherosclerosis, a poten-
tial downregulator of TPM1 could be the small noncoding
microRNAmiR21 [71], as miR21 was the highest upregulated
miRNA in a study of human atherosclerotic plaques [72].
In our study, IL27 induced the upregulation of GBP1 which
was also observed in IFN𝛾-treated HUVECs [73], leading to
enhanced adhesion ofmonocytes. Similar results of increased
adherence of monocytes were demonstrated in stimulated
Human Dermal Microvascular Endothelial Cell (HDMEC)
and Human Coronary Artery Endothelial Cells (HCAEC)
[74].
Based on our data and our hypothetical model, IL27-
induced endothelial inflammation is involved in the recruit-
ment, adhesion, and infiltration of monocytes and of T
cells. Thus, we propose an important proatherogenic role
for IL27 in the early steps of atherosclerosis. Furthermore,
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we observed IL27-induced upregulation of PEBP1 which is
consistent with elevated PEBP1 levels found in atherosclerotic
apoE−/− mice [75]. We also propose an atheroprotective
role for calprotectin, as illustrated in Figure 8. Stimulation
with calprotectin prevented the IL27-mediated upregulation
of NID1 and TPM1, suggesting that no impairment of the
underlying basement membrane is occurring. In addition,
calprotectin reduced IL27-mediated upregulation of theGBP1
which may lead to reduced monocyte adhesion to the
endothelium. Interestingly, calprotectin downregulated the
protein expression of PECAM1, leading to the assumption
of reduced transendothelial migration: PECAM1 is indeed
known as an important contributor for transendothelial
migration of leukocytes into the vessel wall [76].
Comparing the stimulations by IL27 and by IL27 +
calprotectin by IPA pathway analysis (Table S2), we iden-
tified that, regarding the costimulation, calprotectin was
responsible for the inhibition of mTOR as well as of EIF2
signaling pathways. Different groups have observed in animal
and human models that inhibition of mTOR can result in
antiatherosclerotic effects causing prevention or delay of the
pathogenesis of atherosclerosis [77, 78]. Based on our results,
we propose an atheroprotective role for calprotectin through
its IL27-dependent effect on the transendothelial migration
of leukocytes into the vessel wall.
4.2. Hypotheses Regarding the Immunoprotective Role of Cal-
protectin. It has been demonstrated in vivo that calprotectin
reduced LPS-mediated inflammation by binding directly to
LPS but also to other cytokines such as IL1𝛽, IL6, and TNF𝛼
[37]. Another in vivo animal study revealed a reduction of
severe infiltration of inflammatory cells after calprotectin
administration and suggested a scavenger activity for calpro-
tectin [38]. Regarding our experimental setup, based on the
knowledge that calprotectin can bind to TNF𝛼, and since we
showed that calprotectin similarly reduced both TNF𝛼- and
IL27-mediated gene expression, we also suggest a potential
protein-protein interaction between calprotectin and IL27.
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This scavenger function does not directly imply a prevention
of receptor binding and subsequent activation of the signaling
pathway, as it depends on the availability of free binding
sites of IL27. Whether calprotectin can prevent the binding
of IL27 to its receptor requires more investigations. Besides,
it is also well documented that IL27 receptor activation
occurs through Janus kinases and STATs. Interestingly, a
study identified that excretory/secretory (ES) products from
a parasite reduced IFN𝛾-mediated CXCL10 gene expression
without any suppression of the phosphorylation-dependent
activation of the upstream regulator STAT1 [79]. However,
no decrease of CXCL9 mRNA level was observed, which
may be explained by the presence of different transactivating
cofactors required for gene transcription. Whether this regu-
lation process could be extrapolated to the observed different
modulatory effects of calprotectin on IL27-mediated STAT-
dependent CXCL10/CXCL11 gene expression would require
further investigations.
5. Conclusion
In conclusion, our findings clearly demonstrate that the
cytokine IL27 plays an important role as a proinflammatory
mediator by regulating the expression of endothelial genes
and proteins, which may be mainly involved in the early
stages of the atherosclerosis mechanism. More importantly,
we show for the first time that calprotectin acts as amodulator
of this process. Our main findings are the identification of a
role of calprotectin in the regulation of IL27-mediated gene
expression (IL15, CXCL10), protein expression (TPM1, NID1,
PECAM1, and GBP1), and signaling activation (STAT1).
Based on these observations, we suggest that, in the context of
the IL27-induced vascular inflammation, calprotectin might
be a novel attractive candidate as a regulator of monocyte
recruitment to early atherosclerotic lesions, hence preventing
the progression of inflammation and atherosclerosis.
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